Therapy Areas: Oncology
Zelluna awarded NOK16m research grant for Phase 1 cancer study
30 June 2026 - Zelluna ASA (OSE:ZLNA), a Norway-based company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, said on T...
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
30 June 2026 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a California-based biotechnology company involved in the treatment and prevention of cancer, announced on Monday that the Korean Ministry of Inte...
Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK
30 June 2026 - Nuvation Bio (NYSE: NUVB), a New York-based global oncology company involved in cancer treatment, announced on Monday that the Medicines and Healthcare products Regulatory Agency (MHRA)...
Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial
29 June 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ: NTRA) and Aveta Biomics Inc, a clinical-stage immuno-oncology company, on Monday announced a strategic partnership to su...
AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer
29 June 2026 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (NYSE: AZN), announced on Monday that together with Daiichi Sankyo Company Limited, it has received a positive recommenda...
Anivive Lifesciences' Laverdia receives FDA approval to treat canine lymphoma
29 June 2026 - Anivive Lifesciences, a California-based pharmaceutical company, announced on Friday that the US Food and Drug Administration (FDA) Center for Veterinary Medicine has granted full appro...